Infectious Disease Treatment Market Size was valued at USD 71.36 Billion in 2023. The Global Infectious Disease Treatment industry is projected to grow from USD 72.43 Billion in 2024 to USD 79.21 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.92% during the forecast period (2024 - 2032).
Infectious diseases are caused due to organisms such as bacteria, viruses, fungi, or parasites. These diseases can be transmitted through insects, animals or by consuming contaminated food or water or by being exposed to the environment that is infected by these organisms.
Factors such as the rising prevalence of infectious diseases and increasing awareness regarding these diseases are expected to drive the market growth. According to an article published by the World Health Organization (WHO), nearly 50,000 people die suffering from infectious diseases every day.
However, stringent government regulations and low awareness regarding the treatment options in underdeveloped countries are expected to hamper the infectious disease treatment market growth.
The FDA gave approval to Zevtera after an agreement was reached by the two parties involved, Elgiten Pharmaceuticals and Actavis Generics Switzerland, both subsidiaries of Teva Pharmaceuticals Industries Ltd, in April 2024. The approval was accompanied by Priority Review as well as Fast Track and QIDP designations from the FDA. All Zevtera trials were also multicenter; however, all these trials were randomized, controlled, and multinational. In addition to using an antibiotic other than ceftobiprole medocaril[i] within 72 hours before randomization or during the trial.
Today, MicuRx Pharmaceuticals announced that it has qualified for Qualified Infectious Disease Product (QIDP) designation under Generating Antibiotic Incentives Now(GAIN) Act by the US Food & Drug Administration (FDA), as well as Fast Track Designation for contezolid acefosamil(MRX-4) tablet intravenous MRX-I tablet—these are new oxazolidinone antibiotics for treating moderate to severe diabetic foot infection(DFI) without concomitant osteomyelitis. A clinical phase 3 study is currently underway globally investigating oral contezolid in the treatment of patients with DFI. Once submitted, QIDP status gives both products an additional five years’ data exclusivity, concurrently running with eligibility for the Priority Review of its New Drug Application (NDA) for DFI.
Today, Allecra Therapeutics (“Allecra”), an antibiotic resistance-focused biopharmaceutical company, announced that it has received approval from the US FDA for EXBLIFEP®, a therapeutic option in complicated urinary tract infections (cUTIs) inclusive of pyelonephritis in adult patients 18 years and older. Further to this, Allecra also received a marketing exclusivity extension of five years from the FDA under the Generating Antibiotic Incentives Now Act (GAIN Act). Enacted by Congress in the United States, the GAIN Act offers incentives to encourage manufacturers to make new anti-infective therapeutics as Qualified Infectious Disease Products(QIDPs).
The Infectious disease treatment market has been segmented into disease type, treatment, end-user, and region.
Based on disease type, the market has been divided into viral diseases, bacterial diseases, fungal diseases, parasitic diseases, and others.
The infectious disease treatment market, by treatment, has been segmented into antibiotics, antivirals, antifungals, anti-parasitic, and others.
The market, by end-user, has been segmented into hospitals & clinics, ambulatory care centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The infectious disease treatment market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe.
The infectious disease treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The Middle East & Africa market has been segmented into the Middle East and Africa.
Some of the key players operating in the infectious disease treatment market are:
Regional Market Summary
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the infectious disease treatment market owing to the increasing patient population suffering from various types of infectious disease and the growing number of initiatives taken by the government to manage the spread of infectious diseases in the region. According to the Centers for Disease Control and Prevention, there were 54,285 new cases of Salmonella infection in 2017 in the US.
Europe is expected to hold the second-largest position in the infectious disease treatment market owing to the growing awareness and rising patient population suffering from various infectious diseases. According to the WHO, as of 2018, 14 million people in Europe are suffering from hepatitis C.
Asia-Pacific is expected to be the fastest-growing regional market owing to the high patient population suffering from bacterial infectious diseases and the rising number of initiatives taken by governments as well as private institutes to create awareness regarding infectious diseases. According to an article published by the National Center for Biotechnology Information (NCBI) in May 2018, nearly 22% of deaths of children below the age of 5 years in India are caused due to meningitis and pneumonia.
The infectious disease treatment market in the Middle East & Africa is expected to grow slowly, owing to the rising patient population suffering from various types of infectious diseases.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | USD 79.21 Billion |
| CAGR | 8.92% |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Disease Type, Treatment, End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Janssen Global Services, LLC (US), Sanofi (France), GlaxoSmithKline PLC (UK), Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Bayer AG (Germany), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Aurobindo Pharma (India), Dr. Reddy's Laboratories (India), Cipla Inc. (India), Alkem Labs (India), AbbVie Inc. (US) |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers | Factors such as the rising prevalence of infectious diseases. increasing awareness regarding these diseases are expected to drive the market growth |
Frequently Asked Questions (FAQ) :
Infectious disease treatment market is projected to grow at a 8.92% CAGR between 2024-2032
The Americas is expected to lead the infectious disease treatment market.
Increasing prevalence of infectious diseases and rising awareness are the key factors driving the infectious disease treatment market.
Strict government regulations may limit the infectious disease treatment market.
Different end users of the infectious disease treatment market include ambulatory care centers, hospitals and clinics, and others.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
